---
title: Get a Second Opinion on Your Pharma Pricing Data | GPI
description: Run GPI alongside your current pricing data provider and compare both on your own markets. No charge for the evaluation period. Book a 20 minute call.
image: https://info.globalpricing.com/hubfs/Second%20opinion.png
---

[![Global Pricing Innovations](https://info.globalpricing.com/hs-fs/hubfs/GPI%20Main%20logo%20RGB%20white%20text%20large%20hires.png?width=160&height=44&name=GPI%20Main%20logo%20RGB%20white%20text%20large%20hires.png)](https://globalpricing.com)

[The offer](https://info.globalpricing.com/second-opinion#offer) [How we work](https://info.globalpricing.com/second-opinion#overview) [Questions](https://info.globalpricing.com/second-opinion#faq) [Book a call](https://info.globalpricing.com/second-opinion#book)

![](https://info.globalpricing.com/hubfs/Newsletter%20Image%20sizes%20(8).png)

Specialists in pharmaceutical pricing and market access

# Get a second opinion *before you commit to a price.*

Compare our pricing data, platforms and specialists against whatever you use today, on your own markets and therapy areas. Alongside your current provider if you have one, or in place of the spreadsheets, ad hoc requests and part-sourced figures that fill the gap if you do not.

There is no charge for the evaluation period. You cancel nothing, wait for no renewal window, and keep any existing coverage running throughout.

[Book a 20 minute call](https://info.globalpricing.com/second-opinion#book)

[See how a parallel run works](https://info.globalpricing.com/second-opinion#offer)

[How it works](https://info.globalpricing.com/second-opinion#how) [The offer](https://info.globalpricing.com/second-opinion#offer) [Who we are](https://info.globalpricing.com/second-opinion#about) [How teams work with us](https://info.globalpricing.com/second-opinion#overview) [Why teams choose us](https://info.globalpricing.com/second-opinion#why) [What clients say](https://info.globalpricing.com/second-opinion#clients) [Questions](https://info.globalpricing.com/second-opinion#faq) [Book a call](https://info.globalpricing.com/second-opinion#book)

## Three steps, and nothing to commit to

1

### Book a 20 minute call

Tell us what you work on and what you use today, whether that is another provider or a set of spreadsheets. We will tell you plainly whether an evaluation is worth your time.

2

### Agree the scope together

Which markets, which therapy areas, how long. We put the detail in writing before anything starts.

3

### Put it to work on real questions

If you have a provider, run both and compare what each returns. If you do not, run GPI against work where you already know what good looks like.

Trusted by pricing and market access teams at

![Pfizer](https://info.globalpricing.com/hubfs/Client%20logos/Pfizer.svg)

![AstraZeneca](https://info.globalpricing.com/hubfs/Client%20logos/Astrazeneca.svg)

![Novo Nordisk](https://info.globalpricing.com/hubfs/Client%20logos/Novo%20nordisk.svg)

![Moderna](https://info.globalpricing.com/hubfs/Client%20logos/Moderna.svg)

![Jazz Pharmaceuticals](https://info.globalpricing.com/hubfs/Client%20logos/Jazz.webp)

![Clarivate](https://info.globalpricing.com/hubfs/Client%20logos/Clarivate.webp)

The offer

## Whatever you use today, *put us next to it.*

Switching a data provider mid-contract means paying twice or going without cover for a quarter, so the comparison rarely gets made. We remove that cost so it can happen, whether you are locked into a contract today or starting from nothing.

Which of these is you?

I already use a pricing data provider

I do not use a pricing data provider

I want to see the data before anything else

### Run GPI in parallel, at no charge

Keep your current subscription and run GPI alongside it through to the end of your contract, with no charge for the evaluation period. Your therapy areas, your markets, your team. You compare the two datasets on the questions you already ask every week, then decide with evidence rather than a demo.

[Ask about a parallel run](https://info.globalpricing.com/second-opinion#offer-form)

#### What happens next

1. A 20 minute call to check the fit and understand your current setup
2. We agree markets, therapy areas and length, and put it in writing
3. Onboarding for your team, with API access if you need it
4. You run both and compare. If it does not convince you, nothing happens

### Test us on a live asset

A launch price or a licensing decision does not wait for a data subscription to exist. Where there is no provider, the gap gets filled with spreadsheets, free sources and occasional consultants. Bring us one asset and one set of markets and we will run it and show you the output, so you can judge the depth against a question you already care about.

[Check if your project fits](https://info.globalpricing.com/second-opinion#offer-form)

#### What happens next

1. A 20 minute call about the asset and the markets that matter
2. We confirm what we can show and by when
3. You get the output and the working behind it, not just the number
4. If it is useful, we talk about what an ongoing arrangement looks like

### Request a sample data report

Tell us the markets and the therapy area and we will build a sample on them. No platform access, no meeting required. You get a straight look at the granularity, the currency of the data and the sourcing before you spend anyone's time.

[Request a data report](https://info.globalpricing.com/second-opinion#offer-form)

#### What happens next

1. Fill in the form below with your markets and therapy area
2. We build the sample and send it over
3. Take it to your team and see whether it stands up
4. If it stands up, come back and we will show you the rest

### Tell us where you are and we will take it from there

Pick the option above that matches your situation and the form changes to suit. We come back within one working day with what we can offer and what it would involve.

If you would rather go straight to a calendar, you can [book a call instead](https://info.globalpricing.com/second-opinion#book).

We will use your details to respond to this enquiry and to send occasional pricing and market access intelligence. You can unsubscribe at any time.

Scope and length are agreed case by case, and what we can offer depends on the arrangements you already have in place, so the detail gets settled on a short call rather than on this page. Nothing here asks you to cancel anything.

Who we are

## What is Global Pricing Innovations?

Global Pricing Innovations (GPI) is a specialist pharmaceutical pricing and market access intelligence company based in London. GPI builds and maintains its own proprietary dataset covering pricing, reimbursement, HTA and international reference pricing, delivered through two platforms and a consulting team.

**GPI Pulse** shows what has already happened and what is happening now across your markets. **GPI Horizon** looks forwards, forecasting the price a pre-launch asset can support. Consulting applies the same data and methodology directly. Clients include global pharmaceutical companies, biotechs, clinical research organisations and financial institutions.

Unlike generalist data providers, pharmaceutical pricing is the only market GPI serves. That focus is why our data carries expert interpretation rather than raw figures, and why clients work with a named Customer Success Manager rather than a shared support queue.

SPECIALIST EXPERTISE Consulting Get the answer itself when a question needs judgement rather than another platform login. 200+ combined years of pricing expertise UP TO TODAY BEYOND TODAY TODAY GPI Pulse See where prices, reimbursement and HTA decisions stand today, then model what a change in one market does to all the others. GPI Horizon Set a launch price you can defend before you commit to it, with the payer reasoning and the evidence behind it. THE FOUNDATION UNDER EVERYTHING Our proprietary data Over 200 million validated data points, built and maintained in house rather than licensed in, with every figure sourced. 95% data completeness across 60+ pricing markets, refreshed monthly.

How teams work with us

## Four ways in, one agreement

Two platforms, the data underneath them, and a consulting team applying the same methodology directly. Pick the tab that matches what you do.

Platform

**GPI Pulse**

Platform

**GPI Horizon**

Foundation

**Data Intelligence**

Service

**Consulting**

### What has happened, and what is happening now

Pulse holds pack-level prices with history back to 2017 and kept current, reimbursement status, HTA outcomes, cost of treatment by indication, and an IRP matrix with the rules standardised so you can model what a price change in one market does to the rest.

Search by brand, INN, indication or WHO ATC code. Export to Excel or pull through the API into whatever you were already building.

#### Who uses it

- Pricing teams benchmarking corridors and modelling IRP knock-on effects
- Market access teams tracking reimbursement and HTA decisions across markets
- Competitive intelligence teams monitoring price and access moves
- Feasibility teams mapping treatment availability by indication

### What a payer will pay, before you launch

Horizon scores a pre-launch asset across clinical and commercial value attributes, drawing on published HTA decisions, comparator evidence and market-specific payer frameworks, then returns a justified price corridor with the reasoning attached.

Prediction tools ask what similar drugs achieved. Horizon asks a different question: what is this asset worth to payers, and what price does that support? That distinction is why the output holds up when a board or a licensing committee pushes back on the number.

#### Who uses it

- BD&L teams valuing in-licensing candidates before a bid
- Rare disease teams pricing where no direct comparator exists
- Early pipeline teams building Phase 3 investment cases
- Evidence planning leads deciding which endpoints will move payers

### Our own data, built and validated in house

Both platforms sit on the same foundation: a proprietary dataset GPI builds and maintains rather than licenses in. Over 200 million data points across pricing, reimbursement, HTA and cost of treatment, drawn from primary sources and referenced so you can see where any figure came from.

Reference pricing rules arrive with the analysis already done: which countries sit in the basket, which price type is referenced, how often it is revised, and the exemptions that determine whether it moves your price at all. Our specialists do that work before it reaches you.

#### What that means in practice

- Sources visible against the data, so figures survive internal challenge
- Pack-level granularity rather than country averages
- Historical series showing how a market has moved
- API access if you would rather bring the data into your own systems

### When you need the answer rather than the tool

Our consulting team applies the same data and the same value assessment methodology directly: launch pricing strategy, reference basket analysis, analogue benchmarking for orphan assets, portfolio exposure under MFN.

Every external figure passes internal subject matter expert review before it reaches you. Several clients run consulting alongside a subscription rather than instead of one.

#### Typical engagements

- Launch sequence and reference basket analysis across multiple markets
- Value-based price assessment for a single asset
- Portfolio-level policy exposure modelling
- Ad hoc analysis alongside a platform subscription

**Take one, or take all four.** **GPI Pulse**, **GPI Horizon**, the data feed and consulting can be bought as a single agreement or taken on their own, so you pay for the areas where you will see value and nothing else. Whichever you choose, the price is agreed once and covers the scope we set together, so you know the figure before you take it to a budget holder.

[Talk through the options](https://info.globalpricing.com/second-opinion#book)

Why teams choose us

## What a specialist gives you that a generalist cannot

Pharmaceutical pricing sits inside a much larger data business at most of our competitors. It is the only thing that sits inside ours.

### Specialists, not a division

Pharmaceutical pricing and market access is our whole business. No other product line competes for our roadmap, and no generalist dataset gets stretched to fit. Over 200 combined years of pricing expertise sits behind the platforms.

### Proprietary data that survives challenge

Our own value scoring methodology, payer-validated and built in house rather than licensed in, on endpoints drawn from published HTA decisions. Reference pricing rules with the analysis attached. Cost of treatment calculated from dosing and duration rather than inferred from pack price. Every figure carries its source.

### A named person, not a queue

Every client gets a dedicated Customer Success Manager backed by pricing specialists. Data queries are answered within 24 hours and faster when urgent. First insights land within 48 hours of setup.

![GPI pricing specialists working with a client team](https://info.globalpricing.com/hubfs/shutterstock_2552026011.jpg)

## An extension of your team, *not another login*

The figures you take into a launch price sign-off or a licensing committee have your name on them. Every number in GPI carries its source, so when someone senior asks where it came from, you have an answer rather than a caveat.

Onboarding covers your whole team rather than one administrator, and your Customer Success Manager stays with the account instead of rotating out after handover. Where a question needs more than the platform, our consulting team picks it up using the same data and the same methodology, so you are not handed to a different firm halfway through.

95%Data completeness across covered markets

200M+Data points across pricing, reimbursement, HTA and cost of treatment

60+Pricing markets covered, with pack-level detail and history

100+Markets covered for international reference pricing rules

24hrResponse time on data queries, faster when urgent

Top 10Global pharma companies use GPI data and expertise

In their words

## What clients told us when we asked

Collected through our client feedback programme. Some names are withheld at the client's request.

"GPI is always ready to listen, flexible, available, and amenable to all business needs. Pfizer relies heavily on GPI's cost of treatment calculations in order to determine which products we have to report on, and therefore upholding our reputation."

![Pfizer](https://info.globalpricing.com/hubfs/Client%20logos/pfizer%20logo.png)

**Michelle Pardo**Pricing Manager, Pfizer Inc.

"Major impact. As GPI is our only price database provider, we fully trust them. We've been working together for a while and GPI has always met our expectations and solved our problems if any."

![LFB](https://info.globalpricing.com/hubfs/lfb-squarelogo-1408455370843.webp)

**Marc Gauthier-Darnis**Global Market Access Director, LFB

"GPI provided access to highly standardised pharmaceutical pricing and reimbursement data across multiple global markets. It reduced the effort required to source, harmonise, and maintain pricing data from multiple international sources."

![Clarivate](https://info.globalpricing.com/hubfs/Client%20logos/Clarivate.webp)

**Lead Product Manager**Clarivate

"Excellent client focus and willingness to help in a variety of ways, not just 'provide the contracted services'. The willingness to accept client feedback and improve service and data based on it stood out the most."

DL

**Davide Levi**Senior leader, global pharmaceutical company

"In studies where we need to classify countries based on the reimbursement status of approved drugs, competitors and standard of care, GPI is an essential source. Very good customer service and quick assistance with data pull requests."

![Fortrea](https://info.globalpricing.com/hubfs/Fortrea_Switzerland_AG-Logo.jpg)

**Feasibility team**Fortrea

‹

›

Common questions

## Frequently asked questions

If your question is not here, ask us directly. You will get a straight answer on what we can cover for your markets and where you would get the most out of working with us.

### What is a side by side pharmaceutical pricing data evaluation?

\+

A parallel run, sometimes called a side by side evaluation, means running GPI at the same time as your existing pricing data provider, on the same markets and therapy areas, so you can compare both directly. You keep your existing subscription, so there is no gap in coverage and no waiting for a renewal window. Your team uses both on the same therapy areas and markets and compares what each one returns. We agree the scope, the markets and the length together, and there is no charge for the evaluation period.

### What if we do not have a pricing data provider today?

\+

That is a common position and the offer still applies. Many teams handle pricing questions with spreadsheets, free public sources and occasional consultants, which works until a launch or a licensing decision needs figures that hold up. In that case we scope an evaluation around one live asset and one set of markets rather than a parallel run, so you see the output on a question that matters rather than a sample dataset.

### Why is there no charge for the evaluation period?

\+

A demo runs for an hour on a prepared dataset. A parallel run puts both providers against the questions your team asks every week, including the awkward ones that only surface in real work. Those are where datasets differ, and they arrive on their own schedule rather than during a scheduled call. It also settles the fit question early. You will know within the first month how our coverage holds up in the markets you care about, rather than after a contract is signed.

### How is GPI pricing intelligence priced?

\+

One agreed price for the scope we set at the start, built around the markets, therapy areas and team access you need. We will tell you upfront what would change it rather than letting it surface later. Most of the difficulty in buying pricing intelligence is internal rather than commercial, and a single agreed figure with no moving parts is considerably easier to get through a budget holder than a quote with variables attached.

### What is the difference between Pulse and Horizon?

\+

Pulse covers what has already happened and what is happening now: prices, reimbursement decisions, HTA outcomes, cost of treatment and IRP rules across your markets, kept current. Horizon forecasts the price a pre-launch asset can support, scoring it against endpoints drawn from published HTA decisions and weighting them by market-specific payer priorities. Teams often use both, and either works on its own.

### What happens when the evaluation period ends?

\+

You decide. If the comparison does not convince your team, nothing happens and you have lost only the time spent looking. If it does, we agree a subscription that starts when your current arrangement ends, so the two never overlap in cost.

### What support do GPI clients receive?

\+

A dedicated Customer Success Manager, data queries answered within 24 hours and faster when urgent, onboarding and training for your whole team rather than a single administrator, and quarterly business reviews covering usage, product updates and roadmap. First insights are available within 48 hours of setup.

### Does GPI offer an API for pharmaceutical pricing data?

\+

Yes. GPI provides API access across pricing, cost of treatment, IRP and custom endpoints, with documentation and support for the integration. Some teams work entirely in the platform, some pull the data into their own environment, and plenty do both.

Start the conversation

## Book a call with a pricing specialist

Twenty minutes with a pricing specialist. We will ask what you are working on and what you use today, then tell you plainly whether an evaluation is worth setting up.

Pick a time

### Choose a slot that works for you

Twenty minutes with a GPI specialist, at a time that suits you.

Or send us a note

### Not sure which route fits?

Tell us roughly what you are working on and we will come back with the options that make sense for your situation.

Insights

## Insights from our pricing team

[See all insights →](https://globalpricing.com/insights/)

### [Assessment MFN Readiness Assessment Where your portfolio is exposed under Most Favoured Nation pricing, and what to do about it. Take the assessment →](https://info.globalpricing.com/mfn-readiness-gpi)

### [eBook The Pricing Inflection Point How pricing and access pressure is reshaping launch decisions, and where teams still have room to act. Download →](https://globalpricing.com/the-pricing-inflection-point-why-2026-will-redefine-pharma-market-access/)

### [Case study Analogue benchmarking for orphan pricing Pricing a rare disease asset with no direct comparator, and how close the forecast landed. Read the case study →](https://globalpricing.com/analogue-benchmarking-for-orphan-drug-pricing/)

### [Newsletter Pharma Intelligence Brief Monthly analysis of pricing, reimbursement and policy movement across global markets. Subscribe →](https://info.globalpricing.com/newsletter)

![Global Pricing Innovations](https://info.globalpricing.com/hs-fs/hubfs/GPI%20Main%20logo%20RGB%20white%20text%20large%20hires.png?height=38&name=GPI%20Main%20logo%20RGB%20white%20text%20large%20hires.png)

27/28 Eastcastle Street, Eastcastle House, London  ·  [info@globalpricing.com](mailto:info@globalpricing.com)  ·  [globalpricing.com](https://globalpricing.com)

<https://www.linkedin.com/company/global-pricing-innovations>

[Skip to content](https://info.globalpricing.com/second-opinion#main-content)

```json
{
  "@context" : "https://schema.org",
  "@type" : "Organization",
  "address" : {
    "@type" : "PostalAddress",
    "addressCountry" : "GB",
    "addressLocality" : "London",
    "streetAddress" : "27/28 Eastcastle Street, Eastcastle House"
  },
  "description" : "The global pharmaceutical pricing experts. Curated data, enabled by technology, guided by specialist expertise.",
  "logo" : "https://5025153.fs1.hubspotusercontent-na1.net/hubfs/5025153/GPI%20Main%20logo%20RGB%20white%20text%20large%20hires.png",
  "name" : "Global Pricing Innovations",
  "sameAs" : [ "https://www.linkedin.com/company/global-pricing-innovations" ],
  "url" : "https://globalpricing.com"
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "ProfessionalService",
  "address" : {
    "@type" : "PostalAddress",
    "addressCountry" : "GB",
    "addressLocality" : "London",
    "streetAddress" : "27/28 Eastcastle Street, Eastcastle House"
  },
  "areaServed" : "Worldwide",
  "description" : "Pharmaceutical pricing and market access intelligence covering pricing, international reference pricing, HTA and cost of treatment data, delivered through the GPI Pulse and GPI Horizon platforms and a specialist consulting team.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "SoftwareApplication",
        "applicationCategory" : "BusinessApplication",
        "applicationSubCategory" : "Pharmaceutical pricing intelligence",
        "description" : "Global pharmaceutical pricing, reimbursement, HTA, cost of treatment and international reference pricing intelligence platform.",
        "name" : "GPI Pulse",
        "operatingSystem" : "Web browser"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "SoftwareApplication",
        "applicationCategory" : "BusinessApplication",
        "applicationSubCategory" : "Pre-launch price forecasting",
        "description" : "Value-based price forecasting platform for pre-launch and pipeline pharmaceutical assets.",
        "name" : "GPI Horizon",
        "operatingSystem" : "Web browser"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "description" : "Launch pricing strategy, reference basket analysis, analogue benchmarking and portfolio policy exposure modelling.",
        "name" : "GPI Consulting"
      }
    } ],
    "name" : "GPI solutions"
  },
  "image" : "https://5025153.fs1.hubspotusercontent-na1.net/hubfs/5025153/GPI%20Main%20logo%20RGB%20white%20text%20large%20hires.png",
  "name" : "GPI Pharmaceutical Pricing Intelligence",
  "provider" : {
    "@type" : "Organization",
    "name" : "Global Pricing Innovations"
  },
  "serviceType" : "Pharmaceutical Pricing Intelligence & Market Access Consulting",
  "url" : "https://globalpricing.com"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://info.globalpricing.com/second-opinion",
  "@type" : "WebPage",
  "about" : {
    "@type" : "Thing",
    "name" : "Pharmaceutical pricing intelligence"
  },
  "dateModified" : "2026-08-17",
  "description" : "Run GPI alongside your current pharmaceutical pricing data provider and compare both on your own markets, with no charge for the evaluation period.",
  "inLanguage" : "en-GB",
  "isPartOf" : {
    "@type" : "WebSite",
    "name" : "Global Pricing Innovations",
    "url" : "https://globalpricing.com"
  },
  "name" : "Get a Second Opinion on Your Pharmaceutical Pricing Data"
}
```

```json
{
  "@context" : "https://schema.org",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A parallel run, sometimes called a side by side evaluation, means keeping your existing provider and running GPI alongside it, so there is no gap in coverage and no need to wait for a renewal window. Your team uses both on the same therapy areas and markets and compares what each returns. Scope, markets and length are agreed on a call, and there is no charge for the evaluation period."
    },
    "name" : "What is a side by side pharmaceutical pricing data evaluation?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A demo runs for an hour on a prepared dataset. A parallel run puts both providers against the questions a team asks every week, including the awkward ones that only surface in real work. It also settles the fit question early. A client knows within the first month how GPI coverage holds up in the markets that matter to them, rather than after a contract is signed."
    },
    "name" : "Why is there no charge for the evaluation period?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "One agreed price for the scope set at the start, built around the markets, therapy areas and team access required. GPI states upfront what would change the price rather than letting costs surface later, which makes the internal business case simpler to get approved."
    },
    "name" : "How is GPI pricing intelligence priced?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "GPI Pulse covers what has already happened and what is happening now across your markets: prices, reimbursement decisions, HTA outcomes, cost of treatment and international reference pricing rules, kept current. GPI Horizon forecasts the price a pre-launch asset can support, scoring it against endpoints drawn from published HTA decisions and weighting them by market-specific payer priorities. Either works on its own."
    },
    "name" : "What is the difference between GPI Pulse and GPI Horizon?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "The client decides. If the comparison does not convince their team, nothing happens and they have lost only the time spent looking. If it does, GPI agrees a subscription that starts when the current arrangement ends, so the two never overlap in cost."
    },
    "name" : "What happens when a GPI evaluation period ends?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. GPI provides API access across pricing, cost of treatment, international reference pricing and custom endpoints, with documentation and support for the integration. Some teams work entirely in the platform, some pull the data into their own environment, and many do both."
    },
    "name" : "Does GPI offer an API for pharmaceutical pricing data?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "GPI clients receive a dedicated Customer Success Manager, data queries answered within 24 hours and faster for urgent requests, onboarding and training for the whole team, and quarterly business reviews. First insights are available within 48 hours of setup."
    },
    "name" : "What support do GPI clients receive?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Global pharmaceutical companies, biotechnology firms, clinical research organisations and financial institutions. Clients include Pfizer, AstraZeneca, Novo Nordisk, Moderna, Jazz Pharmaceuticals and Clarivate, alongside small and mid-sized biotech teams."
    },
    "name" : "Who does GPI work with?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "The offer still applies. Many teams handle pricing questions with spreadsheets, free public sources and occasional consultants. In that case GPI scopes an evaluation around one live asset and one set of markets rather than a parallel run, so you see the output on a real question. You can also request a sample data report before any conversation."
    },
    "name" : "What if we do not have a pharmaceutical pricing data provider today?"
  } ]
}
```